Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can rofecoxib delay a diagnosis of Alzheimer's disease in patients with mild cognitive impairment?

Nature Clinical Practice Neurology volume 1, pages 20–21 (2005)Cite this article

boxed-textThal LJ et al. (2005) A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30: 1204–1215

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Akiyama H et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383–421

    Article  CAS  Google Scholar 

  2. Walsh S and Aisen PS (2004) Inflammatory processes and Alzheimer's disease. Expert Rev Neurother 4: 793–798

    Article  CAS  Google Scholar 

  3. Martin BK et al. (2002) Double placebo design in a prevention trial for Alzheimer's disease. Control Clin Trials 23: 93–99

    Article  Google Scholar 

  4. Eriksen JL et al. (2003) NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 112: 440–449

    Article  CAS  Google Scholar 

  5. Petersen RC et al. (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352: 2379–2388

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Emma Campbell, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Neurology and Medicine and Director of the Memory Disorders Program at Georgetown University Medical Center, Washington, DC, USA

    Paul S Aisen

Authors
  1. Paul S Aisen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul S Aisen.

Ethics declarations

Competing interests

Dr Aisen has been a paid consultant to Merck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aisen, P. Can rofecoxib delay a diagnosis of Alzheimer's disease in patients with mild cognitive impairment?. Nat Rev Neurol 1, 20–21 (2005). https://doi.org/10.1038/ncpneuro0039

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0039

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing